537 related articles for article (PubMed ID: 27572335)
1. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
2. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
[TBL] [Abstract][Full Text] [Related]
3. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow R; Ruhlmann CH; Garcia-Del-Barrio MA; Schwartzberg L; Rapoport BL; Jahn F
Support Care Cancer; 2023 Dec; 32(1):37. PubMed ID: 38110581
[TBL] [Abstract][Full Text] [Related]
4. 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Roila F; Warr D; Hesketh PJ; Gralla R; Herrstedt J; Jordan K; Aapro M; Ballatori E; Rapoport B
Support Care Cancer; 2017 Jan; 25(1):289-294. PubMed ID: 27510316
[TBL] [Abstract][Full Text] [Related]
5. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
Herrstedt J; Roila F; Warr D; Celio L; Navari RM; Hesketh PJ; Chan A; Aapro MS
Support Care Cancer; 2017 Jan; 25(1):277-288. PubMed ID: 27443154
[TBL] [Abstract][Full Text] [Related]
6. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
7. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
[TBL] [Abstract][Full Text] [Related]
8. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
[TBL] [Abstract][Full Text] [Related]
9. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
[TBL] [Abstract][Full Text] [Related]
11. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.
McKenzie E; Zaki P; Raman S; Olson R; McFarlane T; DeAngelis C; Chan S; Pidduck W; Razvi Y; Bushehri A; Chow E
Support Care Cancer; 2019 Mar; 27(3):783-791. PubMed ID: 30607675
[TBL] [Abstract][Full Text] [Related]
12. 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Warr D; Hesketh PJ
Support Care Cancer; 2017 Jan; 25(1):271-275. PubMed ID: 27501965
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy induced emesis: pathophysiology and prevention].
Mailliez A; Bonneterre J
Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
[TBL] [Abstract][Full Text] [Related]
14. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Ruhlmann CH; Sayegh P; Hesketh PJ
Support Care Cancer; 2023 Dec; 32(1):53. PubMed ID: 38129530
[TBL] [Abstract][Full Text] [Related]
15. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
Ruhlmann CH; Jahn F; Jordan K; Dennis K; Maranzano E; Molassiotis A; Roila F; Feyer P
Support Care Cancer; 2017 Jan; 25(1):309-316. PubMed ID: 27624464
[TBL] [Abstract][Full Text] [Related]
16. 2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
Ruhlmann CH; Jordan K; Jahn F; Maranzano E; Molassiotis A; Dennis K
Support Care Cancer; 2023 Dec; 32(1):26. PubMed ID: 38097904
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
18. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).
Ann Oncol; 1998 Aug; 9(8):811-9. PubMed ID: 9789602
[TBL] [Abstract][Full Text] [Related]
19. Emesis induced by low or minimal emetic risk chemotherapy.
Tonato M; Clark-Snow RA; Osoba D; Del Favero A; Ballatori E; Borjeson S
Support Care Cancer; 2005 Feb; 13(2):109-11. PubMed ID: 15714358
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
